Table 2.
Colorectal Cancer Screening Uptake* among Patients Receiving Usual Care in the Systems of Support to Increase Colorectal Cancer Screening Trial, by Exposure to a Patient-Centered Medical Home
| Usual Care Only | Duration of Exposure to Medical Home (months)
|
||
|---|---|---|---|
| ≤4 (n = 351) |
>4 and<8 (n = 316) |
≥8 (n = 499) |
|
| Primary outcome | |||
| Any CRCS* | |||
| Unadjusted percent (95% CI) | 36.8 (31.9–41.9) | 34.8 (29.7–40.2) | 44.9 (40.6–49.3) |
| Adjusted RR† (95% CI) | 1.00 (Referent) | 0.99 (0.81–1.18) | 1.29 (1.15–1.42) |
| Adjusted difference‡ (95% CI) | Referent | −0.2 (6.9 to 6.5) | 10.1 (5.7–14.6) |
| Secondary outcomes | |||
| Any fecal test§ | |||
| Unadjusted percentage (95% CI) | 21.1 (17.1–25.7) | 20.6 (16.5–25.4) | 32.7 (28.7–36.9) |
| Adjusted RR† (95% CI) | 1.00 (Referent) | 0.99 (0.64–1.35) | 1.58 (1.22–1.94) |
| Adjusted difference‡ (95% CI) | Referent | −0.1 (−7.6 to 7.3) | 12.1 (5.9–18.2) |
| Any endoscopy | |||
| Unadjusted percentage (95% CI) | 21.4 (17.4–26.0) | 20.6 (16.5–25.4) | 18.2 (15.1–21.9) |
| Adjusted RR† (95% CI) | 1.00 (Referent) | 1.03 (0.77–1.29) | 0.95 (0.73–1.18) |
| Adjusted difference‡ (95% CI) | Referent | 0.6 (−4.5 to 5.8) | −0.9 (−5.4 to 3.6) |
Any colorectal cancer screening (CRCS) test included completion of fecal occult blood tests, flexible sigmoidoscopy, or colonoscopy during year 1 of the Systems of Support to Increase Colorectal Cancer Screening Trial (SOS). All patients were overdue for CRCS.
Relative risk (RR) of screening in the exposure group relative to the group with ≤4 months of exposure to a patient-centered medical home (PCMH), adjusted for age, sex, race, education, and prior CRCS.
Adjusted difference is the percentage screened in the exposure group minus the percentage screened in group with ≤4 months of exposure to a PCMH, adjusted for age, sex, race, education, and prior CRCS.
Hemoccult SENSA.
CI, confidence interval.